Streetbeat News

Revenues

DSX

Diana Shipping Inc. (DSX) has entered into a time charter contract with Louis Dreyfus Company for the m/v Crystalia, an Ice Class Panamax dry bulk vessel. The contract, starting in Q2 2024, has a gross charter rate of $13,900 minus a 5% commission, for 21 to 25 months, expected to generate $8.76 million in gross revenue. Following the sale of m/v Houston and m/v Artemis, DSX's fleet will include 38 vessels, with plans to add two methanol dual fuel Kamsarmax vessels by 2028. The current fleet's capacity is about 4.5 million dwt.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 2:19 pm

SRCL

Stericycle (NASDAQ:SRCL) has seen varied analyst opinions over the past three months, with recent evaluations showing a positive trend in price targets. The average 12-month price target is now $62.25, marking a 14.22% increase from the previous average of $54.50. Analysts from Wells Fargo, RBC Capital, Stifel, and Truist Securities have all raised their price targets, reflecting optimism about the company's performance. Despite a -2.73% decline in revenue growth for the last quarter of 2023, Stericycle's financial indicators such as net margin, ROE, and ROA outperform industry averages, suggesting strong profitability and financial health.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 2:00 pm

MYRG

Recent analyst ratings for MYR Group (NASDAQ:MYRG) show a positive trend, with 3 bullish and 1 indifferent rating in the last three months. The average 12-month price target has increased to $170.5, up 7.23% from $159. Analyst actions include ratings and price target adjustments by Stifel and Sidoti & Co., with Goldman Sachs also providing a buy rating. MYR Group's financial performance indicates strong revenue growth and ROE, but challenges in net margin and profitability.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 2:00 pm

PG

Procter & Gamble (NYSE:PG) was analyzed by 10 analysts, showing a mix of bullish to bearish sentiments. The average 12-month price target is $165.2, reflecting a 1.62% increase from the previous target. Analysts' ratings and price targets have been updated, with most showing optimism. P&G's financials indicate strong market position, revenue growth, and profitability, despite challenges in ROE and competition within the Consumer Staples sector.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 2:00 pm

UHS

Universal Health Services (NYSE:UHS) received mixed ratings from 5 analysts, with an updated average 12-month price target of $176.8, marking a 15.93% increase from the previous target. Analysts from TD Cowen, Cantor Fitzgerald, Citigroup, UBS, and Wells Fargo adjusted their ratings and price targets, reflecting a positive outlook based on UHS's financial performance, including a 7.44% revenue growth and strong market capitalization. The company's net margin, ROE, ROA, and debt management were highlighted as exceeding industry benchmarks.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 2:00 pm

EXLS

ExlService Holdings (NASDAQ:EXLS) received mixed analyst ratings with an updated average 12-month price target of $36.5, marking a 14.06% increase from the previous target. The company's financial performance shows strong revenue growth, profitability, and efficient use of equity and assets, with a lower market capitalization and prudent debt management. Analysts from TD Cowen, Needham, Citigroup, and Wedbush provided recent evaluations, adjusting ratings and price targets based on market conditions and company performance.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 2:00 pm

LFWD

ReWalk Robotics Ltd. (DBA Lifeward), announced that CMS has deferred its final decision on the payment rate for personal exoskeletons, affecting the pricing determination for ReWalk Personal Exoskeletons. The decision, part of CMS' HCPCS coding memorandum, means payments will continue on a case-by-case basis. Lifeward has delivered 35 Personal Exoskeletons to Medicare beneficiaries and remains committed to supporting pricing considerations for its stair-enabled ReWalk Exoskeleton.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:48 pm

VEEV

Veeva Systems has revised its FY25 revenue forecast to $2.725B-$2.740B, slightly below the previous estimate of at least $2.75B. The company also projects an adjusted EPS of $6.16, which is above the estimated $5.57. This guidance is for the fiscal year ending January 31, 2025, including non-GAAP operating income of about $1.07B.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:41 pm

SLS

SELLAS Life Sciences announced successful Phase 1 results for SLS009 in treating acute myeloid leukemia (AML) at the 2024 European School of Haematology Conference. The study met all objectives, including pharmacokinetic, pharmacodynamic, safety, and clinical activity. A notable achievement was a complete remission (CR) in a patient after three months, lasting eight months, with one-year survival at the latest assessment. This marks the first instance of CR with CDK9 inhibition monotherapy in a relapsed/refractory AML patient. Phase 2a data is expected in March and Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:31 pm

NFE

New Fortress Energy, Inc. (NFE) has announced the operational status of its Terminal Gas Sul (TGS) LNG terminal in Santa Catarina, Brazil. The terminal, featuring the Energos Winter Floating Storage Regasification Unit (FSRU), has a capacity of approximately 6 MTPA and a maximum send out of 500 mmscf/day. It is connected to the Brazilian gas market, including over 3.5 GW of power infrastructure without firm gas supply contracts and over 300 TBtu of industrial and residential consumers. The TGS terminal is expected to play a crucial role in meeting the increasing power and gas demands in Brazil, especially as the main gas supply from Bolivia declines.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:02 pm